Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权 目录号:S1068

Crizotinib (PF-02341066) Chemical Structure

CAS No. 877399-52-5

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1812.55 现货
RMB 900.49 现货
RMB 1372.81 现货
RMB 4681.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献271篇:

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。
靶点
ROS1 [6]
(Cell-free assay)
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
<0.025 nM(Ki) 11 nM 24 nM
体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞,作用于c-Met磷酸化作用时具有相似效果,IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞,具有相似的活性,且活力增高,IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时,IC50为13 nM。[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时,与作用于野生型受体相比,效果发生显著改变,IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞,也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比,PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍,作用于IRK和Lck选择性高250多倍,作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反,PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值,为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型,和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长,IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡,IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵,IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射,IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活,和Matrigel入侵,IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞,也有效抑制 NPM-ALK磷酸化,IC50 为24 nM。PF-2341066 有效抑制细胞增殖,伴随着使细胞周期停在G(1)-S期,且诱导 ALK阳性的 ALCL 细胞凋亡,IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 [2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长 (例如,增殖和存活)和转移 (例如,入侵和形成克隆)。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MmnRR5l1d3SxeHnjJGF{e2G7 MV:0PEBp MWHEUXNQ Mo[2R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= NHTSNIszOTV5MkW4PS=>
BAF3 MVHDfZRwfG:6aXOgRZN{[Xl? M1;0elQ5KGh? MoXaSG1UVw>? Mm\BR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh|ryP MkHqNlE2PzJ3OEm=
BAF3 NYj2R5liS3m2b4TvfIlkKEG|c3H5 MmHlOFghcA>? NWDjcIpzTE2VTx?= M{LldGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2= M4LQd|IyPTd{NUi5
Kelly Mnn6R5l1d3SxeHnjJGF{e2G7 NGHWemJFVVOR NFfuTopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=> NY\IOG1OOjF3N{K1PFk>
SH-SY5Y M1ezVGN6fG:2b4jpZ{BCe3OjeR?= NV;BWm5TTE2VTx?= MnnrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjV|IN88US=> NVXPUYdmOjF3N{K1PFk>
SMS-KCN NFfSXFBEgXSxdH;4bYMhSXO|YYm= MoDsSG1UVw>? MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQIHPlcIx{KGW6cILld5NqdmdiQVzLJHIyOjd3UTDteZRidnRid3n0bEBKSzVyIH;mJFAvQTFizszN MnWzNlE2PzJ3OEm=
BAF3 MUfDfZRwfG:6aXOgRZN{[Xl? M3\JfFQ5KGh? M4PzXmROW09? MlPZR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP MUCyNVU4OjV6OR?=
3T3 MojQSpVv[3Srb36gRZN{[Xl? NWn4b3p1OSCq NXzsbmpyTE2VTx?= M1\nS2lvcGmkaYTpc44hd2ZiUl;OJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? M3Lw[lIyQDF{NEG0
3T3-E MnS0SpVv[3Srb36gRZN{[Xl? NFvXdmgyKGh? MUXEUXNQ MV;Jcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=> M4rnNVIyQDF{NEG0
A549 Mnf1T4lv[XOnIFHzd4F6 MX[xJIg> M2nIWWROW09? M{XN[GlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=> NF;XUmEzOThzMkSxOC=>
BAF3-BCL NUD3d3FFTnWwY4Tpc44hSXO|YYm= M3vi[lEhcA>? MW\EUXNQ MVrJcohq[mm2aX;uJI9nKEGETDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOS5zNUmg{txO M2TqNFIyQDF{NEG0
HEK293 NG\WPWdHfW6ldHnvckBCe3OjeR?= MWKxJIg> MWrEUXNQ MU\Jcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO M1HiTFIyQDF{NEG0
HEK293 MoG3SpVv[3Srb36gRZN{[Xl? NIjiTmIyKGh? MXLEUXNQ M4Tpd2lvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? MX6yNVgyOjRzNB?=
Jurkat M2C5PWZ2dmO2aX;uJGF{e2G7 MX6xJIg> M4mwRmROW09? NGHPbIhKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh|ryP MXqyNVgyOjRzNB?=
KARPAS299 M3n3cmtqdmG|ZTDBd5NigQ>? MlHiNUBp NG\HVoFFVVOR NV\QNHBvUW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NH;4[XIzOThzMkSxOC=>
PAE MnTrSpVv[3Srb36gRZN{[Xl? MUSxJIg> NXTzO5o6TE2VTx?= NEG0e|FKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= MV[yNVgyOjRzNB?=
BAF3 M1fUN2Z2dmO2aX;uJGF{e2G7 M1rKSVIuOyCm MYnEUXNQ NFfoOIhKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO NGn0PVUzOzd2MkK1Ni=>
KARPAS299 NHXze5VEgXSxdH;4bYMhSXO|YYm= NVzX[IdkOi1|IHS= MlXySG1UVw>? NWPXTok1UUN3ME2wMlA3PDJizszN NEHLO2QzOzd2MkK1Ni=>
EBC1 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\CfWc5PzJiaB?= NUT3U3Q{TE2VTx?= NIOyToJKSzVyPUCuNFI{KM7:TR?= NUjoRVdWOjN7OUOzNlg>
HCT116 NHfpNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDEO|IhcA>? NXKx[45RTE2VTx?= Mnr6TWM2OD1zND64NkDPxE1? NHjnVmgzOzl7M{OyPC=>
MCF7 M4TpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXe3NkBp NFjId4VFVVOR MnfPTWM2OD17LkW4JO69VQ>? MmLCNlM6QTN|Mki=
MDA-MB-231 M3j5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nyTVczKGh? M{DXZmROW09? NFHMRoFKSzVyPUGwMlgh|ryP NEXpZW8zOzl7M{OyPC=>
MKN45 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfGO|IhcA>? MVXEUXNQ NGPOc4ZKSzVyPUCuNFE{KM7:TR?= Ml;jNlM6QTN|Mki=
NCI-H441 NVjQc|h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3DWJk4OiCq NGK3WHBFVVOR NEfIOHVKSzVyPUG3MlI2KM7:TR?= M3rSbVI{QTl|M{K4
NCI-H661 M4HXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLO|IhcA>? MnjPSG1UVw>? MYjJR|UxRTFzLkS3JO69VQ>? NX21bXVYOjN7OUOzNlg>
SK-MEL-28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy3NkBp MYDEUXNQ MVzJR|UxRTFyLkm3JO69VQ>? NX65WY5COjN7OUOzNlg>
SKOV3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rOT|czKGh? M2fFS2ROW09? NHTiOWVKSzVyPUGyMlg2KM7:TR?= M1m2WFI{QTl|M{K4
SNU5 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf4V5A4OiCq NFS2fFhFVVOR NVS4Tm9xUUN3ME2wMlAyPiEQvF2= NV7UNI1KOjN7OUOzNlg>
NCI-H2228 M3v2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnCb3JTPzJiaB?= MVjEUXNQ NWjES5ZIUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? M1fUdFI1PDN{OUC5
NCI-H3122 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXLNmRtPzJiaB?= NEnXWFJFVVOR M3yyOmlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0> MljWNlQ1OzJ7MEm=
NCI-H3122 M3;5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTRZpJEPzJiaB?= MVTEUXNQ MYrJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KHerdHigTWM2OCCxZjCwMlYzOyEQvF2= NYPiNlFvOjR2M{K5NFk>
NCI-H3122 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nB[FczKGh? NYDUeZQ3TE2VTx?= MVLJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= NXSwNXljOjR2M{K5NFk>
NIH-3T3 MVjLbY5ie2ViQYPzZZk> M2fJelEhcA>? MofQSG1UVw>? MlzLTY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhTU2OND3meZNm\CCDTFug[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NWDITGliOjR2M{K5NFk>
NIH-3T3 NFy2NlZMcW6jc3WgRZN{[Xl? M2i5[FEhcA>? NWDO[|JXTE2VTx?= NWf5fnpjUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh|ryP NHjjR2QzPDR|MkmwPS=>
NIH-3T3 M1j2dGtqdmG|ZTDBd5NigQ>? NIDkdoIyKGh? NEn2U|RFVVOR NXK4SYJFUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP M1LQb|I1PDN{OUC5
NIH-3T3 NXPBenI6U2mwYYPlJGF{e2G7 NELEfXoyKGh? MoK4SG1UVw>? MnHFTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC56NEOg{txO NGHiOYEzPDR|MkmwPS=>
NIH-3T3 NH;yT45McW6jc3WgRZN{[Xl? NHXzZncyKGh? MYTEUXNQ MXzJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> MYKyOFQ{OjlyOR?=
BAF3 MoLSSpVv[3Srb36gRZN{[Xl? NVziNVVmPzJiaB?= NHm5eG5FVVOR MoPKTY5pcWKrdHnvckBw\iCQUF2vRWxMKHS{YX7z[oVkfGWmIHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODVzIN88US=> MVeyOFQ3QDZ|Mh?=
BAF3 M1HoTWN6fG:2b4jpZ{BCe3OjeR?= M3zLfFczKGh? MWnEUXNQ NGD0ZWdKSzVyPUCuPVgh|ryP MWOyOFQ3QDZ|Mh?=
NIH-3T3 M4fhXGtqdmG|ZTDBd5NigQ>? NYrKVFZmOSCq MXjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIF[xNVc1VCCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjF4NTFOwG0> MXyyOFgyQTFzNh?=
NIH-3T3 NFfkPYRMcW6jc3WgRZN{[Xl? NF;iWpoyKGh? NWjqcZVIUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD60O|gh|ryP M2rEN|I1QDF7MUG2
NIH-3T3 NI\HZ4JMcW6jc3WgRZN{[Xl? NUn1N25uOSCq MlnJTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVIxOlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5zNEig{txO M4rHSlI1QDF7MUG2
NIH-3T3 M13ycWtqdmG|ZTDBd5NigQ>? MnzzNUBp MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? MoD0NlQ5OTlzMU[=
KARPAS299 NITrTmtMcW6jc3WgRZN{[Xl? NIHaVY86OCCvaX6= NIHnUHdFVVOR MVPJcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0> NF;HW4ozPDlyMEe1NC=>
MKN 45 NEHxTJBMcW6jc3WgRZN{[Xl? MWGxJIg> NUXPTYZiTE2VTx?= M2rGbmlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? NV;tb3FGOjR7MEC3OVA>
A549 NEDwcYJEgXSxdH;4bYMhSXO|YYm= M3;zeFQ5KGh? MnSzSG1UVw>? NIXCPXhKSzVyIH;mJFQvODh2IN88US=> NHTJfVgzPDlyMEizNC=>
NCI-H1975 M4PXbmN6fG:2b4jpZ{BCe3OjeR?= M13vTVQ5KGh? Mo\VSG1UVw>? M{T0NGlEPTBib3[gO{42PTFizszN MVqyOFkxODh|MB?=
NCI-H1993 M3OzeWN6fG:2b4jpZ{BCe3OjeR?= MkTZOFghcA>? NEPXOnVFVVOR NXrwTlU5UUN3MDDv[kAxNjB4MTFOwG0> NITS[HEzPDlyMEizNC=>
NCI-H1993 NW\B[XFZSXCxdH;zbZMhSXO|YYm= MUixJO69VQ>? M{TQbFI1KGh? NH:zOFRFVVOR NF;YT2Vld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz MlOyNlQ6ODB6M{C=
NIH-3T3 NXf1c3dDS3m2b4TvfIlkKEG|c3H5 NFzGTIk1QCCq MYfEUXNQ MYTJR|UxKG:oIECuN|Y1KM7:TR?= NVO5OmhkOjR7MEC4N|A>
EBC1 M1;lUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy3NkBp MUPEUXNQ NF3CZ3lKSzVyIH;mJFAvODB4OTFOwG0> MnW4NlQ6ODB6M{G=
KARPAS299 NVH2fplPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHGT4s4OiCq Mnn1SG1UVw>? MnLwTWM2OCCxZjCwMlIh|ryP M2P4[lI1QTByOEOx
NB1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITQUoZKSzVyPUmxMlk5KG6P MWnTRW5ITVJ?
NCI-SNU-5 NXrZUWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCwTWM2OD1zMEWuO|Uhdk1? MmnjV2FPT0WU
SR M{HX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrlOVdKSzVyPUGyOk4{OSCwTR?= NVzRS29qW0GQR1XS
SF539 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJyND6yOEBvVQ>? MlO2V2FPT0WU
SU-DHL-1 NV:2V5BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjwdo06UUN3ME2zN|YvQDJibl2= NX[4fFhOW0GQR1XS
SCC-3 M3fZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTN3Nj63OkBvVQ>? MV7TRW5ITVJ?
DEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorETWM2OD1|NkmuPUBvVQ>? NEPO[FRUSU6JRWK=
CTV-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnOTFZKSzVyPUW5Ok41QCCwTR?= MYPTRW5ITVJ?
EM-2 NX3wSo5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3RT5dKSzVyPU[wNU4{PCCwTR?= NYH6V5lVW0GQR1XS
MHH-CALL-2 NXLaRVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XRZ2lEPTB;NkiyMlU4KG6P MWnTRW5ITVJ?
KM12 M3;iSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2npZmlEPTB;N{C2Mlkhdk1? MXnTRW5ITVJ?
KINGS-1 M{jYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTd2OT63OUBvVQ>? NYPu[3VzW0GQR1XS
MEG-01 M{fNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HMWGlEPTB;OEW3MlY3KG6P MUjTRW5ITVJ?
BV-173 M37R[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwMEW5PVch|ryP NG\0bZRUSU6JRWK=
LAMA-84 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3GTWM2OD1zLkO4NlgzKM7:TR?= MWPTRW5ITVJ?
KARPAS-299 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\lTWM2OD1zLkSwPFYyKM7:TR?= MWfTRW5ITVJ?
K-562 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwN{KyOlkh|ryP MmK4V2FPT0WU
SK-LMS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\2cGlEPTB;MT63Olg3PyEQvF2= M1uxdHNCVkeHUh?=
MOLT-16 NYC5cm5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TKNmlEPTB;MT65OVU4PSEQvF2= MlH5V2FPT0WU
CMK NVjwOZMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\OOWlEPTB;MT65OlE2QSEQvF2= MXLTRW5ITVJ?
ST486 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJwNEOwO|Mh|ryP MXjTRW5ITVJ?
CI-1 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ixbmlEPTB;Mj60PVY2QSEQvF2= MoHjV2FPT0WU
KP-N-RT-BM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TqUmlEPTB;Mj63NFEzOiEQvF2= MmfiV2FPT0WU
ALL-PO NWLsOXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLWfFVKSzVyPUOuNVgzODdizszN M1zENnNCVkeHUh?=
KS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml65TWM2OD1|LkKxNlI2KM7:TR?= M{XKcXNCVkeHUh?=
Becker MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD12LkKzPVMh|ryP NHzRW4hUSU6JRWK=
GDM-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\MTWM2OD12LkK0OlE4KM7:TR?= NH[wSJJUSU6JRWK=
BC-1 NI\kVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRwNEmyO|ch|ryP M4LEWnNCVkeHUh?=
NB14 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7RS2VUUUN3ME20Mlg{PTJ2IN88US=> M{nvTHNCVkeHUh?=
NOS-1 M1vQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInRRoNKSzVyPUWuN|M5PzRizszN M1TZRnNCVkeHUh?=
MZ1-PC NFK1SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjzTWM2OD13LkiyNVUyKM7:TR?= NITw[3dUSU6JRWK=
A498 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPETWM2OD14LkC4OFc{KM7:TR?= Mne5V2FPT0WU
EW-16 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TOVmlEPTB;Nj6zO|c4OyEQvF2= M2i3UnNCVkeHUh?=
NALM-6 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF30e|VKSzVyPU[uOlg{QDdizszN Mo\2V2FPT0WU
EB-3 NYrnRodMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwMEeyN|Mh|ryP MXnTRW5ITVJ?
697 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXVTWM2OD17LkK0N|I6KM7:TR?= NHnpWZZUSU6JRWK=
Ramos-2G6-4C10 NGn4SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TPUWlEPTB;OT61PVg1OiEQvF2= MWDTRW5ITVJ?
KNS-81-FD NGWwTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILZfmVKSzVyPUmuOlk3PTNizszN M3GxcHNCVkeHUh?=
HUTU-80 NXvNTmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rRSmlEPTB;OT63OFY1OiEQvF2= MXPTRW5ITVJ?
LS-411N M2\5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFyLkC1Olch|ryP NYnOR|RiW0GQR1XS
RPMI-8402 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjSWppkUUN3ME2xNE4yOTZizszN NH7OS|ZUSU6JRWK=
KU812 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\iTWM2OD1zMD6yPVkyKM7:TR?= MWLTRW5ITVJ?
EW-1 NXjYO5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKwTWM2OD1zMD60OFI2KM7:TR?= NEm5SmZUSU6JRWK=
HC-1 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Fd|BzUUN3ME2xNE41QDR2IN88US=> NUnFe2Q{W0GQR1XS
NB69 NFXLOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH6xdVlKSzVyPUGwMlUxPDNizszN MYDTRW5ITVJ?
MFH-ino NEnCNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfiW4RKSzVyPUGwMlg{ODNizszN M3PUdHNCVkeHUh?=
CCRF-CEM MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTZflF5UUN3ME2xNU42QTdizszN MWHTRW5ITVJ?
SK-N-DZ MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi4TWM2OD1zMj6wOFM3KM7:TR?= M4jHbnNCVkeHUh?=
NCI-H720 NV7ZNVN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrOU5pKSzVyPUGyMlE4ODVizszN NEjZZYtUSU6JRWK=
HCC1187 NF3sNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILFUHJKSzVyPUGyMlIxPDFizszN NUnLfplQW0GQR1XS
IST-SL2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jQPGlEPTB;MUKuOFg4OiEQvF2= NHK2SWJUSU6JRWK=
KE-37 M4WzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL4cVBKSzVyPUGyMlc6PjZizszN MUDTRW5ITVJ?
HCC1599 M3fub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPXVG5KSzVyPUGyMlkxPjlizszN MmLqV2FPT0WU
A4-Fuk Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj0TWM2OD1zMj65OVg3KM7:TR?= NFnibnpUSU6JRWK=
NKM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOZ2lEPTB;MUOuNlkzPSEQvF2= NELudJpUSU6JRWK=
BE-13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojwTWM2OD1zMz63PVg6KM7:TR?= MUTTRW5ITVJ?
MV-4-11 NH;4NGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTUTWM2OD1zND6wN|I1KM7:TR?= MlLmV2FPT0WU
OPM-2 NIXDW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF2LkSwPFUh|ryP Mon5V2FPT0WU
KARPAS-422 NGLFTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfMW2hKSzVyPUG0MlUyOjZizszN NWPQd2FxW0GQR1XS
RPMI-8226 NVzXOo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF2Lki5NVUh|ryP MYPTRW5ITVJ?
KARPAS-45 NGjKb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljrTWM2OD1zNT63O|E3KM7:TR?= MUDTRW5ITVJ?
SK-PN-DW M3mycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nUTWlEPTB;MUWuPFY{OSEQvF2= MmTUV2FPT0WU
LC-2 M1LJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn34TWM2OD1zNj6xOVA3KM7:TR?= MlLqV2FPT0WU
NCI-H1648 M3nmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XKNmlEPTB;MU[uNlU1KM7:TR?= MlHiV2FPT0WU
RL95-2 M360NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TKeGlEPTB;MU[uN|k4QCEQvF2= MVzTRW5ITVJ?
KNS-42 NHnkSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TxXmlEPTB;MU[uO|I4PCEQvF2= NFLabpZUSU6JRWK=
RPMI-6666 NX\odJhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTpcpZNUUN3ME2xOk46OjFzIN88US=> NYrLNWZDW0GQR1XS
SIG-M5 NUTCR3F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX1em5KSzVyPUG3MlE6ODNizszN NWfPfWtwW0GQR1XS
VA-ES-BJ NHLPOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CwcGlEPTB;MUeuO|Q2OSEQvF2= M3LOPXNCVkeHUh?=
MONO-MAC-6 NWq0cXQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LPWmlEPTB;MUeuPVMyOiEQvF2= MXfTRW5ITVJ?
LAN-6 M1HCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrDU|NWUUN3ME2xPE44PTV5IN88US=> MVrTRW5ITVJ?
A388 M2PVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF7LkOwOVkh|ryP MUDTRW5ITVJ?
SK-NEP-1 M1H0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr6TWM2OD1{MD6yNVMzKM7:TR?= MYLTRW5ITVJ?
TE-10 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWyVpozUUN3ME2yNE42OjJzIN88US=> M4nZPHNCVkeHUh?=
HL-60 NFXXfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X4OmlEPTB;MkCuPVA6QSEQvF2= NUT3V2pyW0GQR1XS
MC116 M{PTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjWdGo5UUN3ME2yNU44OjJzIN88US=> M{nyOnNCVkeHUh?=
SW962 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13jPGlEPTB;MkGuO|kyPSEQvF2= M2TJVXNCVkeHUh?=
NOMO-1 NVnMdYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LJZWlEPTB;MkKuOlU3PCEQvF2= M3u4fXNCVkeHUh?=
CTB-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ{Lki2O|Eh|ryP MXjTRW5ITVJ?
MRK-nu-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj1ZWtKSzVyPUKyMlkxPzRizszN MnfoV2FPT0WU
GR-ST MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD1{Mz63OkDPxE1? MYTTRW5ITVJ?
HH M4qzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\JeGlEPTB;MkSuNFA{KM7:TR?= M4\Kc3NCVkeHUh?=
NCI-H1963 NIe0PJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe2dmlKSzVyPUK0MlA4QDJizszN MlLEV2FPT0WU
QIMR-WIL NEHtNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq3OWhJUUN3ME2yOE45Pzd{IN88US=> NG\oT45USU6JRWK=
CGTH-W-1 NHvnSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ3LkC3NlMh|ryP NHXzdVRUSU6JRWK=
LP-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXPTWM2OD1{NT62OVUyKM7:TR?= MYfTRW5ITVJ?
NCI-H748 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP5TWM2OD1{Nj61NVM4KM7:TR?= NEKxfoFUSU6JRWK=
PF-382 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjETWM2OD1{Nz6yNlI{KM7:TR?= MVjTRW5ITVJ?
ATN-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX5eoQ3UUN3ME2yO{4{PzN{IN88US=> MmTsV2FPT0WU
L-540 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DSN2lEPTB;MkeuOlQ2QSEQvF2= M3vhfXNCVkeHUh?=
LXF-289 NXTQTHV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrZTWM2OD1{Nz63OVE6KM7:TR?= MorYV2FPT0WU
LS-513 NUPpemxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvwTWM2OD1{OD6xPFA4KM7:TR?= NW\jR5pEW0GQR1XS
NCI-H1581 NGjmToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNyLkO5O|Yh|ryP MXLTRW5ITVJ?
ES6 NHj6b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fUfmlEPTB;M{CuOlg6QSEQvF2= NU\WVmtzW0GQR1XS
SW982 NV3KUpRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPGTWM2OD1|MD64OVY3KM7:TR?= M{KwTHNCVkeHUh?=
DOHH-2 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi3WYlwUUN3ME2zNU42QDl|IN88US=> MnLaV2FPT0WU
DB MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnoOm1KSzVyPUOzMlk1OzFizszN MoLaV2FPT0WU
MPP-89 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELIcZZKSzVyPUO0MlE4PTZizszN NHHqfndUSU6JRWK=
LB831-BLC Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDyTW9[UUN3ME2zOE42OTh2IN88US=> M3[5S3NCVkeHUh?=
NB5 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTFTWM2OD1|ND64OVM2KM7:TR?= NHjhdHZUSU6JRWK=
GB-1 NV;hcppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPVTWM2OD1|NT6wOFY6KM7:TR?= M2HOOXNCVkeHUh?=
TE-15 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLlXVlKSzVyPUO1MlIzOzhizszN MXnTRW5ITVJ?
LC4-1 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf5ZWxKSzVyPUO1MlM5PDdizszN NVjUU|BbW0GQR1XS
NCI-H747 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O4bWlEPTB;M{[uNVM3QSEQvF2= NVnyc5RPW0GQR1XS
NTERA-S-cl-D1 M2H5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOxTWM2OD1|OD63N|Q4KM7:TR?= Mk\KV2FPT0WU
SK-MM-2 NFu2V5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHUeXNKSzVyPUSwMlEyPDZizszN MYfTRW5ITVJ?
TGW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRzLkC1OlMh|ryP MYnTRW5ITVJ?
ONS-76 NIfyZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXkTWM2OD12Mj60PFg{KM7:TR?= MoL1V2FPT0WU
CPC-N M4XIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP0TWM2OD12Mj65PVcyKM7:TR?= MnL6V2FPT0WU
ES4 M{nR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy1dWJKSzVyPUS0MlQyPTNizszN MXHTRW5ITVJ?
Daudi MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Uc3h5UUN3ME20OU4xQDJ5IN88US=> M3vBPXNCVkeHUh?=
MOLT-4 M2\lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR3LkC4OVMh|ryP M17sdnNCVkeHUh?=
HT-144 NWLjS3NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR4LkeyOkDPxE1? NX\L[|hWW0GQR1XS
SW872 M{H6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X3UmlEPTB;NEiuNVk{OyEQvF2= MVTTRW5ITVJ?
D-283MED MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HKeGlEPTB;NEiuN|U1OiEQvF2= MmLLV2FPT0WU
NCI-H2126 M3v1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR6Lki0O|Yh|ryP M2q3fnNCVkeHUh?=
NCI-SNU-16 M4PC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2x[ZJKSzVyPUS5MlIyPDNizszN MljyV2FPT0WU
CESS MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLoTWM2OD12OT61NFg5KM7:TR?= M36wPHNCVkeHUh?=
A101D M1Hkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR7Lkm3N|Yh|ryP NFv3dYxUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pALK / pAKT / pERK / pS6; 

PubMed: 24675041     


H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins.

pROS1 / ROS1; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

pSTAT3 / STAT3; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

PARP / cleaved caspase-3 / Bax / Bcl-2; 

PubMed: 25193856     


The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr.

p-c-Met / c-Met; 

PubMed: 25193856     


Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification).

p-mTOR; 

PubMed: 26384345     


Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.

24675041 25351743 25193856 26384345
Immunofluorescence
LC3 / lysosome; 

PubMed: 26384345     


Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. 

SRC / Met; 

PubMed: 26517812     


Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

α-tubulin; 

PubMed: 26517812     


LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

cytochrome c; 

PubMed: 25193856     


PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red

p-ALK; 

PubMed: 25193856     


PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.

26384345 26517812 25193856
体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm3) 明显衰退,且按43天处理日程处理后,平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上,完全抑制GTL-16肿瘤生长,PF-2341066每天按50 mg/kg剂量处理小鼠,3个月后,只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天,观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型,处理周期为33天,观察到平均肿瘤体积降低53%,且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长,在实验最后一天,抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型,不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤,观察到CD31阳性内皮细胞显著降低,这种作用存在剂量依赖性,说明 MVD 受抑制,且具有相关的抗癌高效性,这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型,显著降低人VEGFA 和IL-8血浆水平,这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤,观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠,具有抗癌高效性,这种作用存在剂量依赖性,处理15天,所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器,及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂,这些与 NPM-ALK 磷酸化和功能受抑制相关。[2] PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长(例如, 增殖和存活)和转移 (例如,入侵和形成克隆)。PF-2341066口服饲喂裸鼠,抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤,引起肿瘤衰退,这与18F-FDG 摄取的缓慢降低相关,且降低葡糖糖转运蛋白 1, GLUT-1的表达。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

生化激酶实验:

使用连续耦合的分光光度测定c-Met催化活性,通过分析NADH消耗率而测定c-Met诱导的ADP产量,这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定Ki值, 在含实验试剂的实验孔中加入不同浓度PF-2341066,然后在37oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验:

[1]

- 合并
  • Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞
  • Concentrations: 0 nM-256 nM
  • Incubation Time: 1小时
  • Method:

    GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上,孔中含培养基,培养基中含10% 胎牛血清(FBS),然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)],处理 24小时。 在调查配体依赖的RTK 磷酸化实验中,加入相应的生长因子,处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时,然后使用含 1 mmol/L Na3VO4的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化,使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时,在4oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸(PY-20)抗体(1:500)中温育20分钟;(d) 再次冲洗7次;(e)在3,3,5,5-四甲基联苯胺过氧化物酶底物中温育,开始显示反应,加入0.09 N H2SO4终止反应; (f)在450 nm 处使用分光光度计测定吸光度。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 450.34
化学式

C21H22Cl2FN5O

CAS号 877399-52-5
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04148066 Recruiting Diagnostic Test: ctDNA blood sample Carcinoma Non-Small-Cell Lung The Netherlands Cancer Institute|Roche Pharma AG July 17 2019 Phase 2
NCT03439215 Recruiting Drug: Lorlatinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale|Clinical Research Technology S.r.l. June 13 2017 Phase 2
NCT02946216 Unknown status Genetic: ctDNA analysis Non-small Cell Lung Cancer Stage III|Non-Small-Cell Lung Cancer Metastatic|Adenocarcinoma of Lung|EGFR Wildtype First People''s Hospital of Hangzhou November 2016 --
NCT02511184 Terminated Drug: Crizotinib|Drug: Pembrolizumab ALK-positive Advanced NSCLC Pfizer|Merck Sharp & Dohme Corp. October 2015 Phase 1
NCT02419287 Unknown status Drug: crizotinib Anaplastic Large Cell Lymphoma ALK-Positive University of Milano Bicocca April 2015 Phase 2
NCT02499614 Unknown status Drug: Crizotinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale December 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Crizotinib (PF-02341066) | Crizotinib (PF-02341066)供应商 | 采购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)价格 | Crizotinib (PF-02341066)生产 | 订购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID